Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Zhou Chengzhi
- Target Recruit Count
- 24
- Registration Number
- NCT04310943
- Locations
- 🇨🇳
Zhou Chengzhi, Guangzhou, Guangdong, China
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT04294160
- Locations
- 🇺🇸
University of California LA Santa Monica Location, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute SC, Nashville, Tennessee, United States
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 97
- Registration Number
- NCT04282018
- Locations
- 🇦🇺
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇦🇺Saint Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
- Conditions
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 71
- Registration Number
- NCT04276493
- Locations
- 🇨🇳
The Third Hospital of Nanchang, Nanchang, Jiangxi, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
- Conditions
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT04261439
- Locations
- 🇺🇸
City of Hope National Medical, Duarte, California, United States
🇺🇸Moores UCSD Cancer Center, La Jolla, California, United States
🇨🇳Novartis Investigative Site, Taipei, Taiwan
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 342
- Registration Number
- NCT04215978
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence (cCARE), San Diego, California, United States
🇺🇸UPMC Hillman Cancer Center (Univ Of Pittsburgh), Pittsburgh, Pennsylvania, United States
🇦🇺Blacktown Cancer And Haematology Centre, Blacktown, New South Wales, Australia
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 500
- Registration Number
- NCT04170283
- Locations
- 🇫🇷
Chu Hopital Lyon Sud, PierreBenite, France
🇮🇹Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi, Pavia, Italy
🇯🇵Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT04164199
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT04068519
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳The Fifth Affiliated Hospital Sun Yat Sen University, Zhuhai, Guangdong, China
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 449
- Registration Number
- NCT04047862
- Locations
- 🇺🇸
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇦🇺St Vincents Hospital, Fitzroy, Victoria, Australia
🇨🇳Beijing Tongren Hospital, Cmu, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.